HMBD-001 in Advanced HER3 Positive Solid Tumours
-
- STATUS
- Recruiting
-
- End date
- Sep 20, 2026
-
- participants needed
- 135
-
- sponsor
- Cancer Research UK
Summary
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in patients with advanced HER3 positive solid tumours. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how these can be treated and what happens to HMBD-001 inside the body and how it affects cancer cells.
Description
HMBD-001 is a type of drug called a monoclonal antibody, which works by targeting a protein called HER3, that is found in high numbers in some types of cancers including those which contain NRG1 gene fusions. By attaching itself to this protein it may then work to kill the cancer cells or to stop them growing.
This is a first-in-human clinical trial which has two parts:
Part A is a 'dose escalation' phase where small groups of patients will receive increasing doses of HMBD-001 to find the safest dose which best targets cancer cells.
- In Arm 1, patients will receive HMBD-001 on its own (as a single agent).
- In Arm 2, patients will receive HMBD-001 given with other anti-cancer drugs (in combination).
Part B is a 'dose expansion' phase where larger groups of patients with specific cancer types, known to have high levels of the protein HER3 or a confirmed NRG1 gene fusion will receive the highest doses of HMBD-001 considered to be safe in Part A either alone as single agent or in combination with other anti-cancer drugs.
The main aims of the clinical trial are to find out:
- The highest dose of HMBD-001 alone and in combination with other anti-cancer drugs that can be given safely to patients.
- More about the potential side effects of HMBD-001 when given alone and in combination with other anti-cancer agents and how they can be managed.
- What happens to HMBD-001 inside the body and how it affects cancer cells.
- The potential anti-tumour activity of HMBD-001 as a single agent and in various combination regimens in specific tumour types of HER3 expressing tumours or tumours with NRG1 gene fusions.
Details
| Condition | Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck |
|---|---|
| Treatment | HMBD-001 |
| Clinical Study Identifier | NCT05057013 |
| Sponsor | Cancer Research UK |
| Last Modified on | 20 December 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer